<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To explore the expression of Cysleine-rich 61(Cyr61) gene in the different subtypes of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and the significance of Cyr61 in the genesis progression, and transformation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and the relationship between Cyr61 and vascular endothelial grown factor (VEGF) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemical S-P were used to detect <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expressions of Cyr61 and VEGF in bone marrow mononuclear cells (BMMNC) from 28 MDS, 12 <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) patients, and 10 <z:mpath ids='MPATH_458'>normal</z:mpath> volunteers </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Expressions of Cyr61 and VEGF were higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients than in controls (P &lt; 0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>The expressions of Cyr61 and VEGF were significantly higher in high risk group (0.3998 +/- 0.2647, 0.4775 +/- 0.1342) than that in low risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> group (0.2213 +/- 0.1465, 0.2872 +/- 0.2341) (P &lt; 0.05), but no significant difference between high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>Expressions of Cyr61 and VEGF protein were higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients than in <z:mpath ids='MPATH_458'>normal</z:mpath> controls (P &lt; 0.05), and were significantly higher in high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> group \[(38.7 +/- 2.9)%, (43.2 +/- 2.7)%\] than in low risk group \[(31.4 +/- 3.1)%, (33.5 +/- 3.4)%\] (P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>Expressions of Cyr61 and VEGF were significantly correlated (r = 0.8762, P &lt; 0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Cyr61 and VEGF may play a role in the <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>